Abbott Laboratories Dossier - Source-backed chat

Abbott Laboratories

ABTNYSE

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)0.72

Intrinsic Value $108.46median of 6 methods · middle span $91-$141based on filings through 31 Mar 2026

Market Price $98.83Price as of 30 Sep 2026

Near fair valueIntrinsic value is 10% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $171B

Enterprise Value $198.3B

Shares Outstanding 1.7B diluted

Moat Rating Narrow

Next Earnings Date21 Oct 2026

Last ex-dividend15 Jul 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Abbott enters the second half of 2026 with strong Medical Devices growth, double-digit comparable growth in the newly added Cancer Diagnostics business, a raised adjusted-EPS outlook and additional diabetes-platform innovation. These positives are balanced by weaker Nutrition performance, sizable Exact Sciences integration requirements, a wide gap between reported and adjusted earnings, and unresolved preterm-infant-formula litigation involving approximately 12,700 individual claimants.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets25 analysts · as of 18 Aug 2026

Low · most bearish analyst$103.00

Mean target$119.40

High · most bullish analyst$135.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$103.0024%

Comparable sales growth falls below guidance as Nutrition remains weak, Cancer Diagnostics decelerates below double digits or Exact Sciences integration costs persist, while remaining preterm-formula claims expand or require further material settlements. Under this outcome, the raised adjusted-EPS guidance would be at risk.

Base CaseCentral scenario

$119.4056%

Matches the consensus mean

Abbott delivers within its 6.5%-7.5% full-year comparable-sales-growth guidance and $5.45-$5.60 adjusted-EPS guidance while Medical Devices and Cancer Diagnostics offset Nutrition weakness. Exact Sciences integration progresses without a material disruption, but acquisition-related expenses and residual formula litigation constrain the risk-reward balance.

Bull CaseUpside scenario

$135.0020%

Medical Devices sustains high-single-digit or better comparable growth, Cancer Diagnostics maintains double-digit expansion after the Exact Sciences acquisition, Libre Duo and other pipeline launches broaden the diabetes franchise, and Abbott delivers at the upper ends of its 2026 sales-growth and adjusted-EPS guidance ranges.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Medical Devices generated 8.4% comparable sales growth in Q2 2026, led by strength in electrophysiology, rhythm management, diabetes care and heart failure.
Cancer Diagnostics generated 13.3% comparable growth in Q2 2026 following completion of the Exact Sciences acquisition.
Abbott raised its full-year 2026 adjusted diluted EPS guidance to $5.45-$5.60 while reaffirming 6.5%-7.5% comparable sales growth guidance.
FDA authorization of Libre Duo 10 Day adds the first authorized dual continuous glucose-ketone sensing system to Abbott's diabetes platform, with a U.S. launch planned for later in 2026.

Key Investment Risks

Nutrition comparable sales declined 3.6% in Q2 2026 and 5.6% in the first half, leaving recovery dependent on pricing actions, new products and improving volumes.
Exact Sciences creates integration and execution risk; Abbott specifically identifies realization and timing of anticipated synergies and benefits as uncertain.
Q2 2026 GAAP diluted EPS was $0.53 versus adjusted diluted EPS of $1.31, reflecting substantial acquisition, amortization, legal-reserve and other specified-item adjustments.
After resolving claims involving approximately 2,000 individuals, Abbott reported roughly 1,700 remaining lawsuits involving approximately 12,700 individual claimants related to preterm-infant formulas.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.